Kate J. Reilley

TL;DR: Large, highly diverse mixture-based libraries can be screened directly in vivo to identify individual compounds, potentially accelerating the development of promising therapeutics.

TL;DR: It is hypothesized that the L‐ and D‐Trp isomers of CJ‐15,208, a natural cyclic tetrapeptide reported to be a κ‐receptor antagonist in vitro, would demonstrate short‐acting, dose‐dependent antagonism in vivo, preventing reinstatement of cocaine‐seeking behaviour.

TL;DR: It is hypothesized that the macrocyclic κ opioid receptor (KOR)‐selective antagonist [D‐Trp]CJ‐15,208 would demonstrate antagonist activity after systemic, that is, s.c. and oral administration.

TL;DR: These peptides represent novel lead compounds for the development of peptide‐based opioid analgesics and were synthesized by a combination of solid‐phase peptide synthesis of the linear precursors, followed by cyclization in solution.

TL;DR: D dose-dependency of angiotensin IV's cognitive enhancement in a C57BL/6J mouse model of novel object recognition and the time-course for these effects are characterized are demonstrated, as well as the identity of residues in the hexapeptide important to these effects and the necessity of actions at angiotsin IV receptors for procognitive activity.